PT  - JOURNAL ARTICLE
AU  - Giovani L. Vasconcelos
AU  - Antônio M. S. Macêdo
AU  - Gerson C. Duarte-Filho
AU  - Arthur A. Brum
AU  - Raydonal Ospina
AU  - Francisco A. G. Almeida
TI  - Complexity signatures in the COVID-19 epidemic: power-law behaviour in the saturation regime of fatality curves
AID  - 10.1101/2020.07.12.20152140
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.12.20152140
4099  - http://medrxiv.org/content/early/2020/07/27/2020.07.12.20152140.short
4100  - http://medrxiv.org/content/early/2020/07/27/2020.07.12.20152140.full
AB  - We apply a versatile growth model, whose growth rate is given by a generalised beta distribution, to describe the complex behaviour of the fatality curves of the COVID-19 disease for several countries in Europe and Asia. We show that the COVID-19 epidemic curves not only may present a subexponential early growth but can also exhibit a similar subexponential (power-law) behaviour in the saturation regime. We argue that the power-law exponent of the latter regime, which measures how quickly the curve approaches the plateau, is directly related to control measures, in the sense that the less strict the control, the smaller the exponent and hence the slower the diseases progresses to its end. The power-law saturation uncovered here is an important result, because it signals to policymakers and health authorities that it is important to keep control measures for as long as possible, so as to avoid a slow, power-law ending of the disease. The slower the approach to the plateau, the longer the virus lingers on in the population, and the greater not only the final death toll but also the risk of a resurgence of infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe gratefully acknowledge partial financial support from CNPq and CAPES Brazil.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No consent was necessary. All the data used in the manuscript are publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset is compiled from data provided by Johns Hopkins University at https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases. https://fisica.ufpr.br/modinterv